spacer
home > pmps > autumn 2017 > convenience, compliance and cartons
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Convenience, Compliance and Cartons

PMPS: Patient adherence is a current hot topic. Why is it of such interest to the industry?

Dr Daniel Keesman: Pharmaceutical companies lose hundreds of billions of dollars every year due to the fact that patients do not stick to their medication plan or do not take the prescribed medicine. Not only do they want to prove that their drugs are effective, pharma companies have an interest in improving adherence and compliance.

In your experience, what have been the biggest obstacles to adherence in pharma packaging over the past 10 years?

Primary packaging has improved in recent years, for instance, by inventing auto injection devices and pens to prevent the patient from seeing the scary needle. Secondary packaging is, unfortunately, very often thrown away, as it only serves as a transportation and value protection. Further, the leaflets are not put into the folding carton again after first use as nobody is able to fold them back to the same size it was when delivered.

Technical devices supporting adherence that could be attached to the packaging – such as displays or near-field communication chips that can be connected to smartphones – only make sense when the drug itself is worth having a packaging that costs 5-20 times more than without such a device.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Daniel Keesman, son of a German mother and a Dutch father, was born in New York, US, and is therefore still an American. For nearly 10 years, he has been part of the executive board of the quality-oriented pharmaceutical packaging manufacturer. He entered August Faller Group as Managing Partner in 2009 and is responsible for the development of national and international markets.
spacer
Dr Daniel Keesman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Oxford Genetics licenses SnapFast™ expression vectors to Twist Bioscience

November 16, 2017, Oxford, England and San Francisco, US. – Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, announced today a new licensing agreement with Twist Bioscience Corporation, a company enabling customers to succeed through its offering of rapid, high-quality synthetic DNA. Oxford Genetics will supply Twist Bioscience with its SnapFast™ technology platform to provide a broad range of application-specific expression vectors which Twist Bioscience will use to clone synthesized DNA for its diverse customer base.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

 
Industry Events

5th Biennial Biosimilars & Biobetters Congress 2018

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global are proud to present our highly anticipated 5thBiennial Biosimilars & Biobetters Congress, 16th – 17thApril 2018, London, UK. Over 450 proteins, peptides and biosimilars delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions will enjoy over 20 presentations and case studies focusing on the key areas of the biosimilars industry including market access strategies, clinical development, commercialisation, manufacturing and bio-analytics
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement